Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
11
×
Tags
life sciences
national blog main
national top stories
roche
11
×
san francisco top stories
11
×
san francisco blog main
biotech
boston blog main
boston top stories
clinical trials
cancer
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
amgen
deals
fda
investing
new york blog main
novartis
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
detroit blog main
detroit top stories
indiana blog main
indiana top stories
merck
pfizer
biogen
biotech ipos
boston
boulder/denver blog main
What
cancer
drug
bio
fda
medicines
patients
roundup
approval
blueprint
data
intended
ipo
life
medical
new
pricing
ret
roche
startup
therapy
address
admits
advanced
advantages
ago
alliance
analytics
annual
approved
approves
arrival
ash
atrophy
award
bar
barcelona
big
biofourmis
biotechs
blood
Language
unset
11
×
Current search:
roche
×
photo
×
" san francisco top stories "
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone